Prot #INCB 18424-365/CINC424D2301: A Phase III, Randomized, Open-Label, Multi-Center Study of Ruxolitinib Versus Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft Versus Host Disease After Allogenic Stem Cell Transplantation

Project: Research project

Project Details

StatusActive
Effective start/end date1/9/181/9/21

Funding

  • DrugDev Inc. (Prot #INCB 18424-365/CINC424D2301)
  • Incyte Corporation (Prot #INCB 18424-365/CINC424D2301)